Published in Case Rep Med on December 05, 2016
The epidemiology of venous thromboembolism. Circulation (2003) 6.97
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet (1994) 5.45
Modulation of oestrogen receptor signalling by association with the activated dioxin receptor. Nature (2003) 3.49
Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Intern Med (2000) 2.77
Cigarette smoking and the risk of venous thromboembolism: the Tromsø Study. J Thromb Haemost (2012) 2.30
Epidemiology and risk factors for venous thrombosis. Semin Hematol (2007) 1.90
Indolo[3,2-b]carbazole: a dietary-derived factor that exhibits both antiestrogenic and estrogenic activity. J Natl Cancer Inst (1994) 1.73
Risk factors for venous thromboembolism: results from the Copenhagen City Heart Study. Circulation (2010) 1.62
Plant-derived 3,3'-Diindolylmethane is a strong androgen antagonist in human prostate cancer cells. J Biol Chem (2003) 1.39
Indole-3-carbinol and diindolylmethane as aryl hydrocarbon (Ah) receptor agonists and antagonists in T47D human breast cancer cells. Biochem Pharmacol (1996) 1.35
Mechanisms of estrogen-induced venous thromboembolism. Thromb Res (2010) 1.05
Smoking and venous thromboembolism: a Danish follow-up study. J Thromb Haemost (2009) 1.05
Current and former smoking and risk for venous thromboembolism: a systematic review and meta-analysis. PLoS Med (2013) 1.01
Indole-3-carbinol is a negative regulator of estrogen. J Nutr (2003) 0.99
Ligand-independent activation of estrogen receptor function by 3, 3'-diindolylmethane in human breast cancer cells. Biochem Pharmacol (2000) 0.96
Interplay of genes regulated by estrogen and diindolylmethane in breast cancer cell lines. Mol Med (2007) 0.87
Identification of estrogen-induced genes downregulated by AhR agonists in MCF-7 breast cancer cells using suppression subtractive hybridization. Gene (2001) 0.86
Effect of diindolylmethane supplementation on low-grade cervical cytological abnormalities: double-blind, randomised, controlled trial. Br J Cancer (2011) 0.85
Hormone replacement therapy and venous thromboembolism. J Steroid Biochem Mol Biol (2013) 0.79